Ontology highlight
ABSTRACT:
SUBMITTER: Okamoto K
PROVIDER: S-EPMC3624778 | biostudies-literature | 2013
REPOSITORIES: biostudies-literature
Current pharmaceutical design 20130101 14
Xanthine oxidoreductase (XOR), a complex flavoprotein, catalyzes the metabolic reactions leading from hypoxanthine to xanthine and from xanthine to urate, and both reactions take place at the molybdenum cofactor. The enzyme is a target of drugs for therapy of gout or hyperuricemia. We review the chemical nature and reaction mechanisms of the molybdenum cofactor of XOR, focusing on molybdenum-dependent reactions of actual or potential medical importance, including nitric oxide (NO) synthesis. It ...[more]